Intelgenx Technologies (IGXT) Return on Equity ROE from the first quarter 2024 to first quarter 2023 and annually, average high and low, overall ranking from Mar 31 2024 to Mar 31 2023 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Intelgenx Technologies Corp   (IGXT)

Intelgenx Technologies 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Intelgenx Technologies in the first quarter 2024?
Due to the lack of equity, it was not possible to calculate Intelgenx Technologies Corp 's return on equity (ROE) in its first quarter 2024

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -11 -10 -11 -11 -11
Return On Equity (TTM) - - - - -
IGXT's Total Ranking # # # # #
Equity (TTM) in Millions -15 -12 -11 -9 -6
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to IGXT Management Effectiveness >> IGXT's 5 Years Annual ROE >> Compare IGXT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





IGXT Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions -12 -3 4 -1 0
Y / Y Equity Change - - - - -97.07 %
Net Income in Millions -10 -11 -9 -7 -11
Y / Y Net Income Change - - - - -
Return On Equity - - -226.38 % - -3638.23 %

Back to IGXT Management Effectiveness >> IGXT's 5 Years Annual ROE >> Compare IGXT ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
IGXT's' Return on Equity at Yahoo Finance
IGXT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for IGXT's Competitors
Subscribers only: Roe for Intelgenx Technologies 's Suppliers
Subscribers only: Return On Equity for IGXT's Customers




Companies with similar Return On Equity at Mar 31 2024, within Healthcare Sector ROE
WEED, INC.  249.65 %
Ladrx Corporation  207.75 %
Glucotrack Inc   207.15 %
Halozyme Therapeutics Inc   192.68 %
Scynexis Inc   122.03 %
Viskase Holdings inc   118.99 %
Mimedx Group Inc   116.14 %
Roivant Sciences Ltd   107.85 %
Entera Bio Ltd   103.40 %
Tenet Healthcare Corp  98.05 %
Davita Inc   88.05 %
Dariohealth Corp   76.11 %
Arcutis Biotherapeutics Inc   69.56 %
Scienture Holdings Inc   66.82 %
Idexx Laboratories Inc  63.66 %
Waters Corporation  63.25 %
Enzo Biochem Inc  61.16 %
Lantheus Holdings Inc   61.14 %
Medpace Holdings Inc   59.74 %
Amgen Inc   58.59 %
Abbvie Inc   55.25 %
Nrc Health  54.83 %
Johnson and Johnson  53.73 %
Eli Lilly And Company  53.13 %
Siga Technologies Inc  51.97 %
Elite Pharmaceuticals Inc   49.73 %
Zoetis Inc   48.39 %
Lite Strategy Inc   48.32 %
Collegium Pharmaceutical Inc   46.81 %
Protagonist Therapeutics inc   43.42 %

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.